STOCK TITAN

MetLife SEC Filings

MET NYSE

Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

MetLife’s balance sheet stewards more than half a trillion dollars in insurance reserves and invested assets—numbers that translate into multi-layered disclosures spanning hundreds of pages. Finding where management explains reserve adequacy or how separate-account assets back variable annuity guarantees can feel daunting.

Stock Titan solves that problem. Our AI engine converts each MetLife annual report 10-K into an easy synopsis, highlights key shifts in credit‐quality of the investment portfolio, and flags loss-ratio trends inside every MetLife quarterly earnings report 10-Q filing. Need rapid context on a dividend declaration or reinsurance treaty? The moment a MetLife 8-K material events filing arrives in EDGAR, we post it with an “8-K material events explained” note. Real-time alerts also cover

  • MetLife Form 4 insider transactions real-time
  • MetLife proxy statement executive compensation
  • MetLife executive stock transactions Form 4
—so you see management’s buying or selling within minutes.

Whether you’re comparing segment profit drivers or monitoring statutory capital, our platform keeps every document at your fingertips: MetLife insider trading Form 4 transactions, MetLife annual report 10-K simplified, MetLife SEC filings explained simply, and MetLife earnings report filing analysis. Stop combing through actuarial footnotes; understanding MetLife SEC documents with AI means you save hours and surface insights faster than ever.

Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

MetLife, Inc. (MET) non‑management director Carla A. Harris acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After this transaction the reporting person beneficially owned 9,048 shares. The filing states these shares represent part of director retainer fees that were elected to be deferred under the MetLife Deferred Compensation Plan for Non‑Management Directors. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 10/03/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Laura J. Hay, a non‑management director of MetLife, Inc. (MET), reported a purchase of 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction, the reporting person beneficially owned 4,261 shares. The Form 4 notes these shares are part of the director retainer that the director elected to defer under the MetLife Deferred Compensation Plan for Non‑Management Directors. The filing was signed by an attorney‑in‑fact on 10/03/2025. The form contains no options or derivative transactions and no other changes to ownership were disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

MetLife, Inc. director Diana McKenzie acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share under the company’s non‑management director compensation program. The filing states that a portion of non‑management director retainer fees are paid in common stock and that Ms. McKenzie elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non‑Management Directors. After this transaction she beneficially owns 22,757 shares, reported as direct ownership. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The disclosure is limited to the director grant and deferral; no additional financial results, guidance, or other transactions are included in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

MetLife, Inc. (MET) non-management director Christian Stephane Mumenthaler reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction he beneficially owned 1,458 shares. The filing states these shares were part of director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The report reflects a routine compensation-related equity grant and deferral by a board member.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

The Form 4 shows that Mark A. Weinberger, a non‑management director of MetLife, Inc. (MET), received 534 shares of MetLife common stock as part of the company's director compensation plan on 10/01/2025. After this award, his beneficial ownership totaled 17,441 shares. The filing states these shares were issued under MetLife's practice of paying a portion of non‑management director retainer fees in common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Robert Glenn Hubbard, a non-management director of MetLife, Inc. (MET), reported an acquisition of 916 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After this transaction, the filing shows 102,067 shares beneficially owned directly by the reporting person.

The filing notes these shares were issued as part of MetLife's non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

MetLife director Carlos M. Gutierrez acquired 534 shares of MetLife, Inc. common stock on 10/01/2025 as part of the company’s non-management director compensation program that pays a portion of retainer fees in common stock. After the purchase, Mr. Gutierrez directly owns 24,385 shares and indirectly holds 18,807 shares through the Carlos M. Gutierrez Trust. The transaction was reported on a Form 4 filed and signed via attorney-in-fact on 10/03/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

MetLife director William E. Kennard reported an acquisition of 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction, the reporting person beneficially owned 44,452 shares. The filing notes these shares were part of non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Some shares are held indirectly through the MetLife Policyholder Trust, which holds shares allocated to eligible policyholders of a MetLife subsidiary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Johnson Jeh C., a non-management director of MetLife, Inc. (MET), reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction the reporting person beneficially owns 7,372 shares. The shares were paid as part of non-management director retainer fees and the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of MetLife (MET)?

The current stock price of MetLife (MET) is $82.89 as of October 14, 2025.

What is the market cap of MetLife (MET)?

The market cap of MetLife (MET) is approximately 53.7B.
MetLife

NYSE:MET

MET Rankings

MET Stock Data

53.75B
663.27M
0.25%
91.63%
1.37%
Insurance - Life
Life Insurance
Link
United States
NEW YORK